Treatment for inflammatory breast cancer and overall survival
This summary table contains detailed information about research studies. Summary tables are a useful way to look at the science behind many breast cancer guidelines and recommendations. However, to get the most out of the tables, it’s important to understand some key concepts. Learn how to read a research table.
Introduction: Inflammatory breast cancer (IBC) is an aggressive form of breast cancer. It’s treated with a combination of chemotherapy, surgery and radiation therapy. Treatment may also include hormone therapy and/or HER2-targeted therapy.
With modern treatments, survival for women with IBC appears to be improving. One study found 3-year overall survival was 63 percent for women diagnosed before 2006 and 82 percent for women diagnosed after 2006 .
Learn more about treatment for IBC.
Study selection criteria: Clinical trials with 50 or more participants and at least 5 years of follow-up.
Study Population (number of participants)
5-year Overall Survival Rate
Palangie et al. 
Chemotherapy>>radiation therapy>>chemotherapy with or without targeted therapy with or without hormone therapy with or without mastectomy
Ueno et al. 
Chevallier et al. 
Chemotherapy>>radiation therapy with or without mastectomy with or without chemotherapy
Attia-Sobol et al. 
Chemotherapy with or without radiation therapy with or without surgery with or without radiation therapy>>chemotherapy
Untch et al. 
Chemotherapy>>mastectomy with or without radiation therapy>>chemotherapy
Perez et al. 
Harris et al. 
Chemotherapy>>radiation therapy with or without mastectomy>>chemotherapy
* Estimate from a figure in the study
† Breast cancer survival rather than overall survival
- Tsai CJ, Li J, Gonzalez-Angulo AM, et al. Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy. Am J Clin Oncol. 38(3):242-7, 2015.
- Palangie T, Mosseri V, Mihura J, et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer. 7:921-7, 1994.
- Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 40:321-9, 1997.
- Chevallier B, Bastit P, Graic Y, et al. The Centre H. Becquerel studies in inflammatory non-metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer. 67:594-601, 1993.
- Attia-Sobol JA, Ferriere J, Cure H, et al. Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis. Eur J Cancer. 29A:1081-1088, 1993.
- Untch M, Möbus V, Kuhn W, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 27(18):2938-45, 2009.
- Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast. II. Inflammatory Carcinoma. Cancer. 74:466-76, 1994.
- Harris EER, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J. Radiation Oncology Biol Phys. 55:1200-1208, 2003.